Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**src siRNA** is a small interfering RNA specifically designed to target and silence the expression of the Src gene, which encodes a non-receptor protein tyrosine kinase involved in regulating cell proliferation, survival, adhesion, migration, and oncogenic processes, particularly in various cancers. The mechanism of src siRNA involves incorporation into the RNA-induced silencing complex (RISC), guiding it to complementary Src mRNA, which is then cleaved and degraded, resulting in reduced protein translation. Experimental data show that src siRNA can reduce Src protein levels by approximately 50–70% in cell models, leading to inhibited cell growth, induction of apoptosis, reduced tumorigenicity, and sensitization to chemotherapeutic agents, especially in triple-negative breast cancer and other malignancies with elevated Src activity[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on src siRNA.